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BACKGROUND: Cancer stem-like cells are a major cause of resistance to therapy in patients
with glioblastoma (GBM) as well as other cancers. Tumor cells are maintained in a stem-like
proliferative state in large part through the Notch signaling pathway. The function of this
pathway in turn depends on gamma secretase activity. Inhibition of this enzyme therefore
inhibits the Notch pathway and tumor growth as measured by a reduction in the formation
of brain tumor neurospheres in murine models. RO4929097 is an oral gamma secretase
inhibitor.
OBJECTIVE: To estimate the 6-mo progression-free survival rate (PFS6 ) in patients with
progressive GBM and to inhibit by 50% the generation of neurospheres in fresh tissue
resected from patients treated with RO4929097.
METHODS: In this phase II and pharmacodynamic study, patients with recurrent
GBM received RO4929097 in a study of 2 groups. Group A patients had unresectable
disease and received drug in a standard phase II design. Group B patients had resectable
disease and received drug before and after surgical resection. Endpoints included PFS6 and
the inhibition of neurosphere formation in the resected tumor samples.
RESULTS: A total of 47 patients received treatment, 7 of whom had tumor resection. The
PFS6 was 4%, and the inhibition of neurosphere formation occurred in 1 of 7 patient
samples.
CONCLUSION: RO4929097 was inactive in recurrent GBM patients and demonstrated
minimal inhibition of neurosphere formation in fresh tissue samples.
KEY WORDS: Gamma secretase, Notch, Pharmacodynamic, Phase 2, Recurrent glioblastoma, RO4929097, Stem
cell
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M

ost patients with glioblastoma (GBM)
suffer disease recurrence within 8 mo
of diagnosis.1 Patients with recurrent
GBM treated on phase 2 trials have a median
survival of 25 wk and a 6 mo progression-free
survival rate (PFS6 ) of 15%.2 Similar pooled
data for patients with recurrent GBM showed
ABBREVIATIONS: ABTC, Adult Brain Tumor
Consortium; CI, confidence interval; CSC, cancer
stem-like cell; GBM, glioblastoma; MRI, magnetic
resonance imaging; PFS, progression-free survival;
RANO, Response Assessment in Neuro-Oncology;
WHO, World Health Organization
Supplemental digital content is available for this article at
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a PFS6 of approximately 10% to 15%.3 With
the exception of bevacizumab, the PFS6 has not
improved with standard chemotherapy regimens
or experimental therapies. Examples of causes of
treatment resistance include insufficient target
modulation, redundant pathways of signal transduction, selective pressure in favor of resistant
tumor clones, hypoxic tumor environments, and
inadequate drug delivery. New agents are needed
to improve the PFS and overall survival (OS) and
quality of life for these patients.
Cancer stem-like cells (CSCs) comprise a
small subset of cells that are capable of
self-renewal within a tumor. They typically
divide slowly and are resistant to radiation and
chemotherapy. Thus, CSCs represent a major
cause of treatment resistance.4 Furthermore,

VOLUME 0 | NUMBER 0 | 2020 | 1

PEEREBOOM ET AL

CSCs promote tumor angiogenesis.5 Therefore, CSCs are an
attractive target for therapy of GBM.
Proliferation of CSCs is driven by several developmental
pathways including the Notch pathway. This pathway consists
of 4 receptors (Notch 1-4) and 5 ligands (DLL 1, 3, and 4, and
JAG 1 and 2).6,7 Activation of Notch signaling imparts a tumor
growth advantage by keeping tumor cells in a stem cell-like proliferative state.8 Because Notch signaling has been associated with
an oncogenic role in multiple cancers, the Notch pathway is a
logical therapeutic target.8
Overexpression of Notch-3 appears to have a role in the
development of certain primary brain tumors.9 Expression of
Notch-1, DLL1, and Jagged-1 is critical for cell survival and
proliferation of human glioma cell lines and primary human
gliomas.10 Gamma secretase (γ -secretase) cleaves the Notch
receptor to form an Notch intracellular domain (N-ICD), which
then moves to the nucleus.7,11 N-ICD becomes part of a
larger transcriptional complex that regulates the transcription
of various target genes. Inhibition of Notch signaling by the
γ -secretase inhibitor LLNIe CHO suppresses growth of cells with
dysregulation of the Notch pathway.12 Furthermore, NOTCH
pathway inhibition appears to deplete CD133+ glioma stem
cells (GSCs) in culture through reduced proliferation and
prolonged survival in nude mice bearing GBM xenografts.13
Thus, disruption of the Notch pathway by inhibition of
γ -secretase is a logical treatment strategy for patients with GBM.
RO4929097 is a selective oral inhibitor of γ -secretase,
producing inhibitory activity of Notch signaling in tumor
cells.14 A phase I trial of RO4929097 determined the most
common toxicities to be nausea, vomiting, diarrhea, fatigue,
hypophosphatemia, and rash.15 The authors observed activity in
1 patient each with colorectal cancer with neuroendocrine
features, sarcoma, and melanoma.15 RO4929097 has variable
blood-brain barrier penetration (tissue concentrations 0.331.3 μmol/L) and target modulation in patients with newly
diagnosed high-grade gliomas.16 That trial demonstrated intratumoral concentrations of the drug comparable with its IC50 values
against human brain cancer cell lines.14,17 Target modulation
included decreases in Notch intracellular domain expression
by tumor cells and blood vessels as well as a decrease in the
population of cancer-initiating cells.16
Based on these data, we conducted a phase II and pharmacodynamic study to assess the efficacy of RO4929097 against recurrent
GBM and to conduct biomarker assays on freshly resected GBM
samples from patients receiving this agent. The overall goal was
to provide proof of principle that CSC-targeted drug therapy
can cross the blood tumor barrier and alter the molecular and
functional aspects of CSCs.

METHODS

Brain Tumor Consortium (ABTC). Two cohorts of adults with recurrent
GBM enrolled concurrently (Figure 1). Group A included 40 patients
with recurrent GBM not amenable to surgery or radiation therapy who
received RO4929097, 20 mg days 1 to 3 every week (3 d on/4 d off
weekly) with a primary endpoint of PFS6 on a standard phase II design.
Group B was an exploratory cohort of up to 20 patients for
whom resection of a recurrent/progressive GBM was clinically indicated.
Patients in this cohort received RO4929097 for 6 d prior to surgical
resection of tumor and then resumed drug upon postoperative recovery.
In addition to clinical endpoints such as PFS and OS, the primary
endpoint for this cohort was the inhibition of neurosphere generation
as well as proliferation of CD133+ neurosphere cells in the tumors of
patients exposed to RO4929097. As a prespecified reference data set
for assessment of the in Vivo effect of RO4929097, the neurosphere
proliferation in resected tumor of Group B patients was modeled after
and compared to those in a contemporaneous ABTC trial of vismodegib
(NCT00980343) with identical entry criteria. In that trial, 20 patients
with recurrent GBM who had not received any preoperative treatment
underwent resection. Those specimens had the identical neurosphere
assays performed in the same lab as the Group B patients in this trial. We
therefore felt that those specimens provided meaningful reference data
on the ability of untreated recurrent GBMs to generate neurospheres.
Postoperatively, Group B patients received RO4929097 on the same
schedule as Group A patients, and were followed for the same clinical
parameters as the Group A patients. Accrual to Group B was to be
suspended if Group A did not reach its primary endpoint.

Patient Eligibility
Eligible patients had histologically proven World Health Organization (WHO) grade IV glioma (2000 WHO classification) that had
progressed or recurred by Response Assessment in Neuro-Oncology
(RANO) criteria after radiation therapy with or without chemotherapy.
Patients were allowed to have received an unlimited number of prior
regimens or resections but no prior γ -secretase inhibitors. Additional
standard eligibility criteria are detailed in Text, Supplemental Digital
Content 1. Patients in Group B were required to have a tumor size
>2.5 cm in diameter with the expectation that at least 50% of the
enhancing portion would be resectable.

Treatment
Group A patients received RO4929097, 20 mg daily on days 1 to
3 every week, with a primary endpoint of PFS6 on a standard phase
II design. Group B patients received RO4929097, 10 mg daily for
6 d preoperatively with up to 4 additional days of dosing permitted for
unexpected delays in surgery. The dose scheduling for the preoperative
therapy was devised empirically with the intent to reach a steady state
serum concentration of drug and to minimize possible toxicity of giving
more than a cumulative total of 60 mg, the total dose administered in
the normal dose schedule (20 mg/d × 3 d). Patients received the last
preoperative dose the evening before surgery. Within 30 d after surgery,
patients resumed drug at the standard dose of 20 mg daily on days 1 to
3 every week until tumor progression. Fresh tumor from Group B
patients was assayed for neurosphere generation.

Study Design

Dose Modifications

This study was a phase II, open label, nonrandomized trial of single
agent RO4929097. The trial was conducted at 6 sites in the Adult

Standard dose modifications were applied as detailed in Text, Supplemental Digital Content 2.
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FIGURE 1. Schema.

Response Assessment
Response to therapy was assessed by standard RANO criteria.18
Magnetic resonance imaging (MRI) was performed every 8 wk, just
prior to every odd-numbered cycle of RO4929097. Complete and
partial responses were to be confirmed by MRI prior to the next cycle,
with the patient returning to the original schedule of having an MRI
every odd-numbered cycle. This schedule was mandated to confirm the
duration of response. Patients were classified as responders if they had a
minimum duration of response for 4 wk at any time after the first cycle
of RO4929097. MRI scans of patients showing tumor response were
reviewed centrally by a neuroradiologist who assessed tumor size independently and computed the percent tumor regression. Adverse events were
graded according to CTCAE version 4.0.

Neurosphere Generation Assays
Functional analysis of tumor stem cells was performed on fresh tumor
samples from Group B patients after evaluation for viability and the
relative presence of necrosis vs tumor. Specimens were cultured in serumfree medium in well-defined stem cell conditions and assessed for their
ability to form neurospheres in serum-free medium as detailed in Text,
Supplemental Digital Content 3.

Statistical Considerations
The study design was intended to determine if PFS6 could be
improved from 10% to 25% in Group A patients. The PFS6 benchmark
of 10% was derived from the combined results of phase II trials in
patients with recurrent GBMs performed in a cooperative group (North
American Brain Tumor Consortium) very similar to the ABTC.3 To
detect this improvement with 90% power, 1-tailed with alpha = 0.1, 40
evaluable patients were required. The study would have been considered
a success if 7 or more patients were progression-free at 6 mo. Secondary
endpoints included radiographic response rate, toxicity and OS.
In Group B, the primary endpoint was suppression of neurosphere
generation after treatment with RO4929097. A 50% reduction in neurosphere generation was considered significant. This degree of reduction
was decided upon arbitrarily since no comparable data existed to describe
a clinically important magnitude of reduction. Approximately 70% of
tumor samples from pretreated GBM patients appear to generate neurospheres.19 The control arm from a contemporaneous randomized trial of
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vismodegib, a hedgehog inhibitor, in which 20 patients with recurrent
GBM underwent resection before drug treatment with assays of neurosphere generation performed in the same laboratory as the samples from
this trial served as a reference cohort. The importance of this reference
cohort is that the tumor samples obtained for neurosphere generation
in that trial were from patients who had not received any preoperative treatment. The trials were performed at approximately the same
time, and the neurosphere formation assays were performed in the same
laboratory for both studies. For this trial, the sample size of Group B was
arbitrarily set at a maximum of 20 to enroll for as long as Group A was
still accruing patients. Further accrual to Group B was to be suspended
if Group A did not reach its primary endpoint. With 20 patients in
each of the 2 surgery groups and doing a direct comparison with Fisher’s
exact test (alpha = 0.05, 1-sided), there would be 90% power to detect
a reduction in development of neurospheres from 70% to 20%.
Time of PFS was calculated from date of treatment started to date
of disease progression or censored at the time of analysis if patient was
free of progressive disease. Time of OS was calculated from date of
treatment started to date of death or censored at the time of analysis
if patients were alive. Baseline patient and disease characteristics were
summarized using standard descriptive summaries. Proportion of PFS6
was estimated using binomial distribution along with 95% CI. OS and
PFS were estimated using the Kaplan-Meier method, and the CIs of
median OS and PFS were constructed by the method of BrookmeyerCrowley.20,21 All adverse events with relationship of possible, or probable,
or definite attribution to RO4929097 were summarized using descriptive
statistics. All analyses were performed using the SAS software, version 9.4
(SAS Institute).

Ethical Approval
All procedures performed in studies involving human participants
were in accordance with the ethical standards of the institutional and/or
national research committee (Cancer Therapy Evaluation Program,
National Cancer Institute) and with the 1964 Helsinki declaration and
its later amendments or comparable ethical standards. This trial was
reviewed and approved by the scientific review committees and institutional review boards at each of the participating institutions. All patients
provided written informed consent before any study procedures were
performed.
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TABLE 1. Patient and Disease Characteristics

Agea
Gender maleb
KPSa
Mini Mental Score
Number of relapsesa
Number of prior surgeries
Steroid use at enrollmentb

TABLE 2. Outcomes

Group A
(n = 40)

Group B
(n = 7)

Total
(n = 47)

58 (35-75)
68% (27)
80 (60-90)
28 (17-30)
2 (1-8)
1.5 (1-3)
35 (14)

56 (34-75)
71% (5)
80 (60-90)
27 (23-30)
1 (1-4)
1 (1-2)
71 (5)

57 (34-74)
68% (32)
80 (60-90)
28 (17-30)
2 (1-8)
1 (1-3)
40 (19)

Cyclesa
PFS6 %c
PFS monthsc
OS monthsc
Responsesb
CR
PR
SD
PD
Inevaluable

a

Median (range).
Percent (N).
KPS = Karnofsky Performance Status.

b

Group A
(n = 40)

Group B
(n = 7)

Total
(n = 47)

5 (0.1-17)
1.7 (1.2-1.8)
7.0 (5.4-9.1)

0
1.6 (0.8-2.3)
6.9 (0.8-11)

1 (1-4)
4 (0-14)
1.7 (1.2-1.8)
7.0 (5.4-9.1)

2% (1)
0

2(1)
0
6 (3)
81 (38)
11 (5)

a

Median (range).
Best response, percent (N).
c
Median (95% CI).
b

RESULTS
Patient Characteristics
A total of 47 patients – 40 in Group A and 7 in Group B – were
enrolled from 6 ABTC participating centers between February
2011 and May 2012. Manuscript submission was delayed by
several changes in first authorship as well as data acquisition
from the ongoing reference trial. All 47 patients were eligible and
evaluable for toxicity, with 40 patients evaluable for response.
Seven patients enrolled in Group B from 5 sites. Because Group
B was an exploratory cohort, it was halted after the drug was
determined to be ineffective based on clinical outcomes of
patients in Group A. Table 1 summarizes the pretreatment
patient and disease characteristics. All patients are off
study.
Safety
Therapy was overall well tolerated with no unexpected toxicities and no treatment related grade 4 or 5 toxicities. In Group
A, grade 3 treatment-related toxicities included 4 patients with
hypophosphatemia and 1 each with elevated alanine aminotransferase, cognitive disturbance, fatigue, and skin infection. Group
B patients had no grade 3 treatment-related toxicities. A full list
of toxicities with a possible, probable, or definite relationship
to RO4929097 is included in Table, Supplemental Digital
Content 4.
Efficacy
The primary endpoint for Group A (PFS6 ) was 5%
(95% CI: 0.06%-17%), well below the goal of 25%. Among all 47
patients, the PFS6 was 4% (0.05%-14%). One patient in Group
A achieved a complete response but no other patients had a radiographic response. Efficacy data are summarized in Table 2, with
the PFS illustrated in Figure 2.
Neurosphere Generation
Specimens from 6 of the 7 (86%) patients generated viable
neurospheres and CD133+ neurospheres.
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FIGURE 2. Progression-free survival.

DISCUSSION
Key Results
This trial did not achieve its primary goal of producing a
PFS6 of 25% with RO4929097 in patients with recurrent GBM.
RO4929097 allowed the formation of neurospheres in 6 of
7 (86%) tumor samples. The number of samples was small as
the trial was halted after Group A accrual was completed, with
RO4929097 having failed to meet its efficacy endpoint. At that
time, 7 patients had been accrued in Group B.
Despite treatment with RO4929097, tissue from 6 out of
7 patients generated neurospheres in Group B. This rate compares
unfavorably to both arms of the sister study ABTC-0904, in
which 11 of 19 (58%) of the untreated patients in Arm II and
3 of 20 (15%) of the patients pretreated with vismodegib (Arm I)
generated viable CD133+ neurospheres (unpublished data).

www.neurosurgery-online.com
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Limitations
The failure of RO4929097 to inhibit neurosphere generation relative to controls from ABTC-0904 could have resulted
from several causes. One possibility is that the drug did not
reach the tumor. A clinical trial of RO4929097 in high-grade
gliomas demonstrated tumor tissue concentrations of approximately 0.7 to 0.8 μmol/L in both enhancing and nonenhancing
tissues.16 These values in the low micromolar range were similar
to IC50 values against human glioma tumor-initiating cells.14,17
While the tumor tissue concentration data (0.7-0.8 μmol/L)
were generated in newly diagnosed high-grade gliomas, the
patients in this trial had recurrent disease after radiation
therapy. Prior radiation therapy can decrease blood brain
barrier permeability, thus decreasing drug delivery to the brain
tumor.22
While additional biomarker assays were not performed in this
trial due to the lack of neurosphere inhibition, RO4929097
appears to inhibit γ -secretase as suggested by reductions in
the expression of Notch intracellular domain, the immediate
product of γ -secretase-mediated cleavage of the inner domain
of the Notch receptor.16,23 It is not clear, however, that the
degree of γ -secretase inhibition was sufficient to affect GSC
proliferation in Vivo in the setting of recurrent GBM. Alternatively, it is also possible that γ -secretase inhibition by itself
is insufficient to inhibit GBM CSC proliferation. It is also
possible that the preoperative regimen of 10 mg/d continuously
was insufficient to reach the tumor. This dose was chosen so
that patients would have drug exposure continuously leading
up to the day before surgery. The risk of the trial schedule of
20 mg/d for 3 of 7 d was that unforeseen delays in surgery by
1 or more days could substantially decrease the amount of drug
available for blood-brain barrier penetration or target inhibition
or both.
Interpretation and Generalizability
These results are disappointing in light of xenograft data that
demonstrate that Notch pathway blockade depletes stem-like cells
in GBMs, suggesting that γ -secretase inhibitors may be useful as
chemotherapeutic agents to target CSCs in high-grade gliomas.13
One of the strengths of this study is that the assays of neurosphere
generation were performed in the same lab and at the same time
as those from a contemporaneous control population. This study
does have some weaknesses. The sample size of Arm B was small,
as a result of the study being halted by design once the accrual goal
for Arm A had been reached. The small number in group B was
not surprising given the difficulty of enrolling surgical candidates
for the studies in recurrent GBM. Biomarkers of Notch activity
were not repeated for this report. This decision was made by the
correlative laboratory once it was determined that the clinical and
neurosphere endpoints were not reached. Confounding factors
for the interpretation of these data include the small sample
size, lack of randomization, and comparison of PFS6 to historic
controls.
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CONCLUSION
RO9729097 is not an active agent against recurrent GBM as
assessed in this and other trials. This agent demonstrated minimal
inhibition of neurosphere formation in fresh tissue samples. CSCs
remain an attractive target for the therapy of GBM. As with
most therapies in GBM as well as other cancers, CSC inhibition
may contribute to clinical activity in the setting of combination
therapies.24
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COMMENT

T

he stem-like proliferative state of glioblastoma cells may be
maintained by the Notch signaling pathway whose function depends
on gamma secretase activity. This phase II, open label, non-randomized
multicenter clinical trial tested the efficacy of RO4929097 (a gamma
secretase inhibitor) in patients with recurrent glioblastoma. One group
was treated with drug at recurrence, while others were treated with drug
prior to resection. The trial was based on results of a Phase 0/1 trial
of the same agent in newly diagnosed patients. The study endpoints
were to measure progression-free survival at 6 months and inhibition of
neurosphere formation in resected tumor samples. In the end, this was a
negative study; data analysis suggested R04929097 did not affect tumor
recurrence or significantly inhibit neurosphere formation. The reasons
for this lack of efficacy are likely myriad; the study design, although
innovative, was not pure and the number of patients small; the drug
may have lacked penetration into the central nervous system or the
ability to modulate glioblastoma cells or post-radiation hypoxia may
have limited it’s efficacy. Nonetheless, novel therapeutic approaches to
glioblastoma are an important aspect of the crusade against this disease.
Mature and well-equipped clinical and basic science groups such as this
are the best avenue for progress. An age-old axiom is that we learn as
much from our failures as our successes. Negative trials provide valuable
benefit in directing increasingly scarce research money in new directions
that may hold more promise. Although not effective in this study, the
promise of gamma secretase inhibition remains viable; the goal is to find
the right combination of anti-proliferative, anti-angiogenic, and antiinvasive therapies for glioblastoma.
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